Inhibikase Therapeutics, Inc. Research and Development Expense
Inhibikase Therapeutics, Inc. (IKT) reported Research and Development Expense of $13.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $13.39M, a 154.10% increase year-over-year.
- Inhibikase Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $10.84M, a 3.10% increase year-over-year.
- Inhibikase Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $6.36M, a 11.60% decline year-over-year.
- Inhibikase Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $7.65M, a 82.58% increase year-over-year.
- Inhibikase Therapeutics, Inc. research and development expense for fiscal 2025 was $29.79M, a 73.11% increase from fiscal 2024.
- Inhibikase Therapeutics, Inc. research and development expense for fiscal 2024 was $17.21M, a 26.38% increase from fiscal 2023.
- Inhibikase Therapeutics, Inc. research and development expense for fiscal 2023 was $13.62M, a 13.16% increase from fiscal 2022.
- Inhibikase Therapeutics, Inc. research and development expense for fiscal 2022 was $12.03M, a 5.95% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.39M 10-Q · filed 2026-08-11 | $24.23M 10-Q · filed 2026-08-11 | $30.59M derived: sum of 3 quarters · filed 2026-08-11 | $38.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $10.84M 10-Q · filed 2026-05-12 | $17.20M derived: sum of 2 quarters · filed 2026-05-12 | $24.85M derived: sum of 3 quarters · filed 2026-05-12 | $30.12M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $6.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $14.01M derived: sum of 2 quarters · filed 2026-03-26 | $19.28M derived: sum of 3 quarters · filed 2026-08-11 | $29.79M 10-K · filed 2026-03-26 |
| 2025-09-30 | $7.65M 10-Q · filed 2025-11-14 | $12.92M derived: sum of 2 quarters · filed 2026-08-11 | $23.43M 10-Q · filed 2025-11-14 | $30.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $5.27M 10-Q · filed 2026-08-11 | $15.78M 10-Q · filed 2026-08-11 | $22.98M derived: sum of 3 quarters · filed 2026-08-11 | $27.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $10.51M 10-Q · filed 2026-05-12 | $17.71M derived: sum of 2 quarters · filed 2026-05-12 | $21.90M derived: sum of 3 quarters · filed 2026-05-12 | $24.97M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $7.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $11.38M derived: sum of 2 quarters · filed 2026-03-26 | $14.46M derived: sum of 3 quarters · filed 2026-03-26 | $17.21M 10-K · filed 2026-03-26 |
| 2024-09-30 | $4.19M 10-Q · filed 2025-11-14 | $7.27M derived: sum of 2 quarters · filed 2025-11-14 | $10.02M 10-Q · filed 2025-11-14 | $13.02M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $3.08M 10-Q · filed 2025-08-14 | $5.83M 10-Q · filed 2025-08-14 | $8.83M derived: sum of 3 quarters · filed 2025-08-14 | $12.06M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.75M 10-Q · filed 2025-05-14 | $5.75M derived: sum of 2 quarters · filed 2025-05-14 | $8.98M derived: sum of 3 quarters · filed 2025-05-14 | $13.52M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $6.23M derived: sum of 2 quarters · filed 2025-03-27 | $10.76M derived: sum of 3 quarters · filed 2025-03-27 | $13.62M 10-K · filed 2025-03-27 |
| 2023-09-30 | $3.23M 10-Q · filed 2023-11-14 | $7.76M derived: sum of 2 quarters · filed 2023-11-14 | $10.62M 10-Q · filed 2023-11-14 | $13.67M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | $4.54M 10-Q · filed 2023-08-14 | $7.39M 10-Q · filed 2023-08-14 | $10.44M derived: sum of 3 quarters · filed 2024-05-15 | $13.43M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | $2.85M 10-Q · filed 2024-05-15 | $5.91M derived: sum of 2 quarters · filed 2024-05-15 | $8.89M derived: sum of 3 quarters · filed 2024-05-15 | $11.87M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $6.04M derived: sum of 2 quarters · filed 2024-03-27 | $9.02M derived: sum of 3 quarters · filed 2024-03-27 | $12.03M 10-K · filed 2024-03-27 |
| 2022-09-30 | $2.98M 10-Q · filed 2023-11-14 | $5.96M derived: sum of 2 quarters · filed 2023-11-14 | $8.98M 10-Q · filed 2023-11-14 | $12.37M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $2.98M 10-Q · filed 2023-08-14 | $6.00M 10-Q · filed 2023-08-14 | $9.39M derived: sum of 3 quarters · filed 2023-08-14 | $12.54M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $3.02M 10-Q · filed 2023-05-15 | $6.41M derived: sum of 2 quarters · filed 2023-05-15 | $9.56M derived: sum of 3 quarters · filed 2023-05-15 | $11.94M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $6.54M derived: sum of 2 quarters · filed 2023-03-31 | $8.93M derived: sum of 3 quarters · filed 2023-03-31 | $11.36M 10-K · filed 2023-03-31 |
| 2021-09-30 | $3.15M 10-Q · filed 2022-11-14 | $5.54M derived: sum of 2 quarters · filed 2022-11-14 | $7.97M 10-Q · filed 2022-11-14 | $8.20M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $2.38M 10-Q · filed 2022-08-12 | $4.81M 10-Q · filed 2022-08-12 | $5.04M derived: sum of 3 quarters · filed 2022-08-12 | $5.16M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $2.43M 10-Q · filed 2022-05-16 | $2.66M derived: sum of 2 quarters · filed 2022-05-16 | $2.78M derived: sum of 3 quarters · filed 2022-05-16 | $3.04M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $226.94K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $347.51K derived: sum of 2 quarters · filed 2022-03-31 | $610.69K derived: sum of 3 quarters · filed 2022-03-31 | $893.80K 10-K · filed 2022-03-31 |
| 2020-09-30 | $120.57K 10-Q · filed 2021-11-15 | $383.74K derived: sum of 2 quarters · filed 2021-11-15 | $666.86K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $263.18K 10-Q · filed 2021-08-16 | $546.29K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $283.11K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |